10-Q: SI-BONE Reports Q1 2026 Results: Revenue Up 11.2%

SI-BONE, Inc. reported its first quarter 2026 financial results, showing an 11.2% increase in revenue to $52.6 million, driven by higher U.S. procedure volumes and expanded product adoption.

Summary

• SI-BONE, Inc. reported first quarter 2026 revenue of $52.6 million, an 11.2% increase compared to $47.3 million in the first quarter of 2025.
• The company's net loss for the quarter was $4.3 million, an improvement from a net loss of $6.5 million in the prior year's first quarter.
• Operating expenses increased by 4.1% to $47.0 million, primarily due to higher sales and marketing costs.
• Cash and marketable securities totaled $144.7 million as of March 31, 2026.
• The company expects its current cash and marketable securities to fund operations for the next 12 months.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive filing, with revenue growth and a narrowing net loss being key positives, though the ongoing net loss and potential future capital needs present areas of caution.

Positives

• Revenue increased by 11.2% to $52.6 million for the three months ended March 31, 2026, compared to $47.3 million for the same period in 2025.
• Gross profit increased by 11.3% to $41.9 million, with gross margin remaining stable at 79.8%.
• Net loss improved to $4.3 million from $6.5 million in the prior year's quarter.
• International revenue saw a significant increase of 33.9% to $3.3 million.
• The company's U.S. commercial organization expanded with more territory sales managers, clinical support specialists, and third-party sales agents.
• Over 33% of U.S. sacroiliac joint procedures were performed in ambulatory surgical centers (ASCs) and office-based labs (OBLs) during the quarter.
• Trailing twelve month average revenue per territory sales manager increased to approximately $2.2 million from $2.0 million.

Negatives

• The company incurred a net loss of $4.3 million for the quarter.
• Total operating expenses increased by 4.1% to $47.0 million.
• Interest income decreased by 15.2% to $1.4 million due to lower interest rates on investments.
• Cash and cash equivalents decreased by $8.7 million during the quarter, ending at $33.5 million.

Risks

• The financial impact of a potential economic downturn or capital market disruptions pose risks to future available capital resources.
• The company may need to raise additional capital if available resources are consumed more rapidly than expected due to decreases in sales, changes in business strategy, regulatory and reimbursement developments, or increased R&D spending.
• The need for additional capital to fund inventory for new product offerings may limit the number of revenue opportunities pursued.
• The U.S. Department of Justice is investigating the company under the federal Anti-Kickback Statute and Civil False Claims Act, requesting information on meals and consulting service payments to healthcare professionals. The outcome is uncertain and could materially impact the business.
• The company relies on a limited number of suppliers, including sole source suppliers, which may impact the availability of instruments and materials.
• Factors impacting supply chains, including tariffs and availability of raw materials and skilled labor, could increase costs and impact prices.

Future Outlook

The company believes its existing cash and marketable securities will fund its operating expenses and capital expenditure requirements over the next 12 months. However, potential economic downturns or capital market disruptions pose risks. The company may need to raise additional capital if resources are consumed faster than expected due to factors like decreased sales, changes in business strategy, regulatory developments, or increased R&D spending. The introduction of new products may also increase the need for capital to fund inventory and instrument trays.

Management Comments

• We are a leader in developing and commercializing differentiated solutions targeting surgical and interventional procedures for patients with compromised bone.
• Our product development strategy focuses on addressing unmet clinical needs while leveraging our existing platform technologies, enabling us to expand surgeon adoption and increase procedure volumes over time.
• Robust clinical evidence is central to drive adoption and favorable reimbursement, and we remain focused on continuing to set the industry standard in delivering evidence-based care through best-in-class clinical trials that demonstrate the efficacy, safety, and economic benefit of our solutions.
• Our ability to recruit and retain skilled personnel, particularly within our commercial organization, is a significant determinant of our success.
• We continue to focus on operational efficiency, including increasing sales force productivity, and optimizing utilization of our instrument trays.

Industry Context

StockSavvy.ai notes that SI-BONE's focus on developing and commercializing differentiated solutions for patients with compromised bone, particularly in the sacroiliac joint, spinopelvic fixation, and pelvic trauma areas, aligns with a growing trend in orthopedic surgery towards minimally invasive procedures and anatomy-specific implants. The company's strategy of leveraging existing platform technologies and investing in R&D to address unmet clinical needs is a common approach in the competitive medical device sector.

Comparison to Industry Standards

• SI-BONE's R&D spending as a percentage of revenue was 8.0% for Q1 2026, which is within the typical range for medical device companies, though some innovative companies may spend higher percentages.
• The company's gross margin of 79.8% is strong and generally above the average for many manufacturing industries, reflecting the specialized nature of its products.
• The increase in revenue of 11.2% is a solid growth rate, indicating market acceptance and effective commercial strategies, which is competitive within the orthopedic device market.
• The company's focus on clinical evidence and FDA breakthrough device designations suggests a commitment to innovation and regulatory pathways that are standard for advancing medical technologies.

Legal Proceedings

• The company received a civil investigative demand (CID) from the U.S. Department of Justice, Civil Division, in October 2024, related to an investigation under the federal Anti-Kickback Statute and Civil False Claims Act. The CID requests information and documents primarily relating to meals and consulting service payments provided to health care professionals. The company is cooperating but cannot estimate the duration, outcome, or potential financial impact, which could be material.

Stakeholder Impact

• Shareholders: Continued net losses and potential need for future capital raises could impact share value. Revenue growth and improved loss metrics are positive indicators.
• Employees: The company emphasizes enhancing employee experience, retention, and professional development, suggesting a focus on its workforce.
• Customers (Healthcare Providers): Continued product innovation and clinical evidence support adoption and patient care.
• Suppliers: The company has purchase commitments and relies on third-party manufacturers, indicating ongoing relationships and potential supply chain considerations.

Next Steps

• Continue to invest in research and development initiatives to bring new and differentiated solutions to the market.
• Expand sales organization, increase surgical capacity, and broaden site-of-service adoption.
• Focus on increasing the number of active physicians performing procedures, improving time to first case, and increasing procedures per active physician.
• Continue to focus on operational efficiency, including increasing sales force productivity and optimizing utilization of instrument trays.
• Work with suppliers to improve supply chain efficiency, lower manufacturing costs, and reduce cash investment in inventory.

Key Dates

Recommendation

The company shows positive revenue growth and a narrowing net loss, indicating operational improvements. However, the continued net loss, significant accumulated deficit, and the ongoing DOJ investigation introduce considerable uncertainty. While the company's core business appears to be growing, these factors warrant a cautious 'hold' stance until the investigation's outcome is clearer and profitability is achieved.

Keywords

SI-BONE, 10-Q, Quarterly Report, Medical Devices, Orthopedics, Spine Surgery, Sacroiliac Joint, Spinopelvic Fixation, Pelvic Trauma, Revenue, Net Loss, Financial Results